AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11688021 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmandibular Implant (TMI group, n = 29)
Number of subjects: 87
Study 11688021 — intervention group
Group type: COMPARATOR
Intervention: IMZ and Brånemark implants
Number of subjects: 87
Study 9844984 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with complex partial epilepsy
Number of subjects: 30
Study 9844984 — intervention group
Group type: COMPARATOR
Intervention: Normal children
Number of subjects: 30
Study 8299783 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide
Number of subjects: 53
Study 8299783 — intervention group
Group type: COMPARATOR
Intervention: Spironolactone
Number of subjects: 53
Study 2087977 — intervention group
Group type: EXPERIMENTAL
Intervention: Postaural aids with modified skeleton moulds
Number of subjects: 0
Study 2087977 — intervention group
Group type: COMPARATOR
Intervention: Temporary tips or standard skeletons
Number of subjects: 0
Study 2087977 — intervention group
Group type: COMPARATOR
Intervention: In-the-ear aids
Number of subjects: 0
Study 393027 — intervention group
Group type: EXPERIMENTAL
Intervention: Enterobiotic (antibiotic prophylaxis)
Number of subjects: 134
Study 393027 — intervention group
Group type: COMPARATOR
Intervention: Control (no antibiotic prophylaxis)
Number of subjects: 134
Study 30484016 — intervention group
Group type: EXPERIMENTAL
Intervention: Catgut embedding
Number of subjects: 510
Study 30484016 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 510
Study 30484016 — intervention group
Group type: COMPARATOR
Intervention: Medication
Number of subjects: 510
Study 28295766 — intervention group
Group type: EXPERIMENTAL
Intervention: Veterinarian-administered otic gel (Group A)
Number of subjects: 50
Study 28295766 — intervention group
Group type: COMPARATOR
Intervention: Owner-administered treatment (Group B)
Number of subjects: 50
Study 25467586 — intervention group
Group type: EXPERIMENTAL
Intervention: AF-219, 600 mg twice a day
Number of subjects: 24
Study 25467586 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 23636409 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraventricular recombinant tissue plasminogen activator (rt-PA) combined with external ventricular drainage (EVD)
Number of subjects: 19
Study 23636409 — intervention group
Group type: COMPARATOR
Intervention: External ventricular drainage (EVD) alone
Number of subjects: 19
Study 20615594 — intervention group
Group type: EXPERIMENTAL
Intervention: Hi-TENS combined with PCA-morphine
Number of subjects: 42
Study 20615594 — intervention group
Group type: COMPARATOR
Intervention: PCA-morphine alone
Number of subjects: 42
Study 19203821 — intervention group
Group type: EXPERIMENTAL
Intervention: Without metronome guidance
Number of subjects: 44
Study 19203821 — intervention group
Group type: COMPARATOR
Intervention: With metronome guidance (100 bpm)
Number of subjects: 44
Study 16462013 — intervention group
Group type: EXPERIMENTAL
Intervention: Impedance spectroscopy in group 3 (more than 4h of ischemia and complications)
Number of subjects: 63
Study 16462013 — intervention group
Group type: COMPARATOR
Intervention: Impedance spectroscopy in group 1 (no ischemia or complications)
Number of subjects: 63
Study 16462013 — intervention group
Group type: EXPERIMENTAL
Intervention: Impedance spectroscopy in group 2 (short ischemia < 2h)
Number of subjects: 63
Study 15370790 — intervention group
Group type: EXPERIMENTAL
Intervention: Health pessimists
Number of subjects: 456
Study 15370790 — intervention group
Group type: COMPARATOR
Intervention: Good-health realists
Number of subjects: 456
Study 15370790 — intervention group
Group type: EXPERIMENTAL
Intervention: Health optimists
Number of subjects: 456
Study 15370790 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor-health realists
Number of subjects: 456
Study 15370790 — intervention group
Group type: EXPERIMENTAL
Intervention: Discordance cases
Number of subjects: 456
Study 11560127 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH-[1-24] (250 mg in 500 mL normal saline, infused at a constant rate over 8 h)
Number of subjects: 10
Study 11560127 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline only)
Number of subjects: 10
Study 9592913 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyography on extensor muscles (extensor carpi radialis brevis and extensor digitorum)
Number of subjects: 51
Study 9592913 — intervention group
Group type: EXPERIMENTAL
Intervention: Torque measurements and histologic observations from muscular and tendon biopsies
Number of subjects: 51
Study 7843475 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 plasma glucose and insulin determinations
Number of subjects: 16
Study 7843475 — intervention group
Group type: EXPERIMENTAL
Intervention: 26 plasma glucose and insulin determinations
Number of subjects: 16
Study 7843475 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of blood samples from 26 to 12
Number of subjects: 16
Study 7843475 — intervention group
Group type: COMPARATOR
Intervention: Glucose effectiveness
Number of subjects: 16
Study 2662897 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon and descyclovir therapy
Number of subjects: 36
Study 2662897 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 36
Study 2662897 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon therapy
Number of subjects: 36
Study 4413468 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha biofeedback training for 1 hour
Number of subjects: 21
Study 4413468 — intervention group
Group type: COMPARATOR
Intervention: Control group (resting under similar conditions but given different instructions and no feedback)
Number of subjects: 21
Study 31201041 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Flow Nasal Oxygen (HFNO) at 50 L/min
Number of subjects: 50
Study 31201041 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilevel Positive Airway Pressure (BIPAP) with pressure support 4 cmH2O
Number of subjects: 50
Study 31201041 — intervention group
Group type: COMPARATOR
Intervention: Standard Oxygen Therapy (SOT) via a standard facemask
Number of subjects: 50
Study 31201041 — intervention group
Group type: EXPERIMENTAL
Intervention: BIPAP with increased pressure support to 8 cmH2O
Number of subjects: 50
Study 31201041 — intervention group
Group type: EXPERIMENTAL
Intervention: BIPAP with increased PEEP to 8 cmH2O
Number of subjects: 50
Study 31201041 — intervention group
Group type: EXPERIMENTAL
Intervention: BIPAP with pressure support 8 cmH2O
Number of subjects: 50
Study 28982202 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined strength‐endurance training (CT)
Number of subjects: 28
Study 28982202 — intervention group
Group type: COMPARATOR
Intervention: Physical activity education program (EDU)
Number of subjects: 28
Study 25299520 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week supervised neuromuscular and strength exercise program
Number of subjects: 82
Study 25299520 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopic partial meniscectomy
Number of subjects: 82
Study 23085134 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg orally)
Number of subjects: 0
Study 23085134 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21266003 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine plus morphine sulfate
Number of subjects: 34
Study 21266003 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 34
Study 19139846 — intervention group
Group type: EXPERIMENTAL
Intervention: Cruciate retaining implants
Number of subjects: 101
Study 16930699 — intervention group
Group type: EXPERIMENTAL
Intervention: ARC organizational intervention
Number of subjects: 26
Study 16930699 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 26
Study 15253862 — intervention group
Group type: EXPERIMENTAL
Intervention: Kava
Number of subjects: 51
Study 15253862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 11767219 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of labour
Number of subjects: 74
Study 11767219 — intervention group
Group type: COMPARATOR
Intervention: Serial antenatal foetal monitoring
Number of subjects: 74
Study 9253908 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard fat emulsion dose (L)
Number of subjects: 57
Study 9253908 — intervention group
Group type: COMPARATOR
Intervention: Withholding fat infusions (NL)
Number of subjects: 57
Study 8490316 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (2 mg/kg for induction)
Number of subjects: 28
Study 8490316 — intervention group
Group type: COMPARATOR
Intervention: Thiopental (4 mg/kg for induction)
Number of subjects: 28
Study 8490316 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (1 mg/kg after intubation)
Number of subjects: 28
Study 8490316 — intervention group
Group type: COMPARATOR
Intervention: Thiopental (2 mg/kg after intubation)
Number of subjects: 28
Study 8490316 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperventilation
Number of subjects: 28
Study 3539256 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal drain
Number of subjects: 112
Study 3539256 — intervention group
Group type: COMPARATOR
Intervention: No drain (non-drainage group)
Number of subjects: 112
Study 28865169 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational intervention (EA-MI)
Number of subjects: 226
Study 28865169 — intervention group
Group type: COMPARATOR
Intervention: Health education control
Number of subjects: 226
Study 27185372 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg fulvestrant
Number of subjects: 134
Study 27185372 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg fulvestrant
Number of subjects: 134
Study 27185372 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant (both dosages)
Number of subjects: 134
Study 24091594 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ibandronate (3 mg quarterly)
Number of subjects: 6064
Study 24091594 — intervention group
Group type: COMPARATOR
Intervention: Oral alendronate (70 mg weekly)
Number of subjects: 6064
Study 22302780 — intervention group
Group type: EXPERIMENTAL
Intervention: STAR educational programme
Number of subjects: 68
Study 22302780 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 68
Study 20536646 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 or 90 mg
Number of subjects: 0
Study 20536646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17803701 — intervention group
Group type: EXPERIMENTAL
Intervention: PCOS women
Number of subjects: 75
Study 17803701 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 75
Study 15844503 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiologists using criteria of important mucosal swelling, air-fluid level or complete opacity
Number of subjects: 80
Study 15844503 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiologists using criteria of air-fluid level or complete opacity
Number of subjects: 80
Study 15844503 — intervention group
Group type: EXPERIMENTAL
Intervention: ENT surgeons using criteria of important mucosal swelling, air-fluid level or complete opacity
Number of subjects: 80
Study 15844503 — intervention group
Group type: EXPERIMENTAL
Intervention: ENT surgeons using criteria of air-fluid level or complete opacity
Number of subjects: 80
Study 15844503 — intervention group
Group type: EXPERIMENTAL
Intervention: General practitioners using criteria of important mucosal swelling, air-fluid level or complete opacity
Number of subjects: 80
Study 15844503 — intervention group
Group type: EXPERIMENTAL
Intervention: General practitioners using criteria of air-fluid level or complete opacity
Number of subjects: 80
Study 12885819 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related quality of life (HRQOL) assessments in RCTs
Number of subjects: 8445
Study 11249411 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotton cover gowns
Number of subjects: 0
Study 11249411 — intervention group
Group type: COMPARATOR
Intervention: No cotton cover gowns (Control)
Number of subjects: 0
Study 8879436 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestradiol (2 mg/day) alone
Number of subjects: 80
Study 8879436 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestradiol (2 mg/day) with norethisterone (1 mg/day)
Number of subjects: 80
Study 8879436 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestradiol (2 mg/day) alone (sub-set of 32 patients)
Number of subjects: 80
Study 8879436 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestradiol/norethisterone (1 mg/day)
Number of subjects: 80
Study 1994666 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI (Spin Echo, multislice‐multiphase technique on the short‐axis plane)
Number of subjects: 32
Study 6723349 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release formulation of ketoprofen (2 capsules of 100 mg once daily)
Number of subjects: 46
Study 6723349 — intervention group
Group type: COMPARATOR
Intervention: Conventional capsule formulation of ketoprofen (100 mg capsules twice daily)
Number of subjects: 46
Study 30409490 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab with pegylated liposomal doxorubicin (PLD)
Number of subjects: 391
Study 30409490 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab with topotecan
Number of subjects: 391
Study 30409490 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab with weekly paclitaxel
Number of subjects: 391
Study 30409490 — intervention group
Group type: COMPARATOR
Intervention: Weekly paclitaxel
Number of subjects: 391
Study 30409490 — intervention group
Group type: COMPARATOR
Intervention: PLD
Number of subjects: 391
Study 30377220 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient tobacco cessation and exposure reduction program for parents of hospitalized children, including education about resources like the Colorado QuitLine.
Number of subjects: 192
Study 30377220 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational interventions for clinical staff regarding smoking cessation resources.
Number of subjects: 192
Study 30377220 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational interventions regarding hospital cessation resources.
Number of subjects: 192
Study 30377220 — intervention group
Group type: EXPERIMENTAL
Intervention: Support for free nicotine replacement therapy.
Number of subjects: 192
Study 25619495 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified algorithm for lymph node sampling
Number of subjects: 1051
Study 25619495 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized sonographic classification system
Number of subjects: 1051
Study 24589124 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 500
Study 24589124 — intervention group
Group type: COMPARATOR
Intervention: Atosiban
Number of subjects: 500
Study 23273213 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary pain programme with minimal interventional procedures
Number of subjects: 0
Study 23273213 — intervention group
Group type: COMPARATOR
Intervention: Multidisciplinary pain programme alone
Number of subjects: 0
Study 20452382 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiar faces (Familiar)
Number of subjects: 29
Study 20452382 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfamiliar faces (Other)
Number of subjects: 29
Study 20452382 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel faces (Novels)
Number of subjects: 29
Study 20452382 — intervention group
Group type: COMPARATOR
Intervention: Behavioral test of face memory
Number of subjects: 29
Study 20452382 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-stage facial identity processing
Number of subjects: 29
Study 17346807 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular desloratadine treatment
Number of subjects: 37
Study 17346807 — intervention group
Group type: COMPARATOR
Intervention: On-demand desloratadine treatment
Number of subjects: 37
Study 16193613 — intervention group
Group type: EXPERIMENTAL
Intervention: Information leaflet
Number of subjects: 1024
Study 16193613 — intervention group
Group type: COMPARATOR
Intervention: No leaflet (Control)
Number of subjects: 1024
Study 12972521 — intervention group
Group type: EXPERIMENTAL
Intervention: EC plus LND (B group)
Number of subjects: 506
Study 12972521 — intervention group
Group type: EXPERIMENTAL
Intervention: EC plus G-CSF (C group)
Number of subjects: 506
Study 12972521 — intervention group
Group type: EXPERIMENTAL
Intervention: EC plus LND plus G-CSF (D group)
Number of subjects: 506
Study 12972521 — intervention group
Group type: COMPARATOR
Intervention: EC alone (A group)
Number of subjects: 506
Study 10759819 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity continuous wave ultrasound (3 W/cm2, 1 MHz for 10 minutes)
Number of subjects: 19
Study 10759819 — intervention group
Group type: COMPARATOR
Intervention: Extremely low-intensity ultrasound (placebo, 0.3 W/cm2, 1 MHz for 10 minutes)
Number of subjects: 19
Study 10759819 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity continuous wave ultrasound
Number of subjects: 19
Study 10759819 — intervention group
Group type: COMPARATOR
Intervention: Extremely low-intensity ultrasound (placebo)
Number of subjects: 19
Study 8674092 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone 600 mg
Number of subjects: 30
Study 8674092 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control Group A)
Number of subjects: 30
Study 1985380 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-to-long protocol
Number of subjects: 77
Study 1985380 — intervention group
Group type: COMPARATOR
Intervention: Standard protocol
Number of subjects: 77
Study 6628707 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg dl-norgestrel and 0.1 mg ethinylestradiol administered orally at 18 hours after LH rise and again at 30 hours
Number of subjects: 5
Study 6628707 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo) cycle
Number of subjects: 5
Study 31838462 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning carbohydrate-restriction diet (MCR-D)
Number of subjects: 70
Study 31838462 — intervention group
Group type: COMPARATOR
Intervention: Mediterranean diet (Med-D)
Number of subjects: 70
Study 31838462 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 70
Study 30678759 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse plaque characteristics (positive remodeling or low attenuation plaque)
Number of subjects: 1769
Study 30678759 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive disease
Number of subjects: 1769
Study 30678759 — intervention group
Group type: EXPERIMENTAL
Intervention: Both obstructive disease and adverse plaque
Number of subjects: 1769
Study 30678759 — intervention group
Group type: COMPARATOR
Intervention: Normal coronary arteries
Number of subjects: 1769
Study 28247479 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted lopinavir (LPV/r)
Number of subjects: 16
Study 28247479 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz (EFV)
Number of subjects: 16
Study 25132248 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-8 (IL-8)
Number of subjects: 811
Study 25132248 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophils
Number of subjects: 811
Study 24091849 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin + Paclitaxel (TP) 45 mg/m²/week
Number of subjects: 93
Study 24091849 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin + Docetaxel (DP) 20 mg/m²/week
Number of subjects: 93
Study 24091849 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin + Gemcitabine (GP) 350 mg/m²/week
Number of subjects: 93
Study 21840467 — intervention group
Group type: EXPERIMENTAL
Intervention: AquADEKs chewable tablets
Number of subjects: 50
Study 21840467 — intervention group
Group type: EXPERIMENTAL
Intervention: AquADEKs capsules
Number of subjects: 50
Study 21840467 — intervention group
Group type: EXPERIMENTAL
Intervention: AquADEKs liquid
Number of subjects: 50
Study 21840467 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamins A (3 mg daily), E (200 mg daily), and D(3) (20 μg daily)
Number of subjects: 50
Study 21840467 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy children)
Number of subjects: 50
Study 19646229 — intervention group
Group type: EXPERIMENTAL
Intervention: CPR training (6 hours)
Number of subjects: 147
Study 17192960 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 254
Study 17192960 — intervention group
Group type: COMPARATOR
Intervention: Abciximab
Number of subjects: 254
Study 17192960 — intervention group
Group type: EXPERIMENTAL
Intervention: SVG patients
Number of subjects: 254
Study 17192960 — intervention group
Group type: COMPARATOR
Intervention: Non-SVG patients
Number of subjects: 254
Study 17192960 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus presence
Number of subjects: 254
Study 17192960 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesion length > 20 mm
Number of subjects: 254
Study 17192960 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis in myocardial infarction flow < 3 post-procedure
Number of subjects: 254
Study 17192960 — intervention group
Group type: EXPERIMENTAL
Intervention: >1 target lesion
Number of subjects: 254
Study 17192960 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentricity
Number of subjects: 254
Study 15097304 — intervention group
Group type: EXPERIMENTAL
Intervention: Enrollment in the preventive HIV vaccine trial
Number of subjects: 2531
Study 15097304 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothetical willingness to enroll
Number of subjects: 2531
Study 15097304 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic factors affecting enrollment
Number of subjects: 2531
Study 15097304 — intervention group
Group type: EXPERIMENTAL
Intervention: Concerns about vaccine-induced seropositivity
Number of subjects: 2531
Study 15097304 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to enrollment for African Americans
Number of subjects: 2531
Study 11736674 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane anaesthesia
Number of subjects: 26
Study 11736674 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane anaesthesia
Number of subjects: 26
Study 9434921 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin III concentrate to achieve 100% activity (n=10)
Number of subjects: 24
Study 9434921 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin III concentrate to achieve 175% activity (n=9)
Number of subjects: 24
Study 9434921 — intervention group
Group type: COMPARATOR
Intervention: Control group received saline 0.9% (n=5)
Number of subjects: 24